ID

33478

Description

Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation (n3); ODM derived from: https://clinicaltrials.gov/show/NCT01810003

Lien

https://clinicaltrials.gov/show/NCT01810003

Mots-clés

Versions (1)
  1. 10/12/2018 10/12/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

10 décembre 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Cardiovascular Disease, Inflammation NCT01810003

Anglais

Eligibility Cardiovascular Disease, Inflammation NCT01810003

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
men and women aged between 18 and 70 years with metabolic syndrome as defined by the international diabetes federation (idf) criteria
Description

Age | Metabolic Syndrome

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0524620
stable body weight for at least 3 months prior to randomization.
Description

Stable body weight

Type de données

boolean

Alias
UMLS CUI [1]
C0517386
pre-menopausal women with regular menstrual cycle (25-35 days)
Description

Premenopausal state | Menstrual cycles regular

Type de données

boolean

Alias
UMLS CUI [1]
C0232969
UMLS CUI [2]
C2229012
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
plasma crp > 10 g/ml at screening
Description

Plasma C-reactive protein measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0428493
extreme dyslipidemias such as familial hypercholesterolemia
Description

Dyslipidemias Extreme | Hypercholesterolemia, Familial

Type de données

boolean

Alias
UMLS CUI [1,1]
C0242339
UMLS CUI [1,2]
C0205403
UMLS CUI [2]
C0020445
previous history of cardiovascular disease (coronary heart disease, cerebrovascular disease or peripheral arterial disease) and type 1 or 2 diabetes or patients having received or being treated with insulin or a thiazolidinedione within the past 6 months
Description

Cardiovascular Disease | Coronary heart disease | Cerebrovascular Disorder | Peripheral Arterial Disease | Diabetes Mellitus, Insulin-Dependent | Diabetes Mellitus, Non-Insulin-Dependent | Insulin | Thiazolidinediones

Type de données

boolean

Alias
UMLS CUI [1]
C0007222
UMLS CUI [2]
C0010068
UMLS CUI [3]
C0007820
UMLS CUI [4]
C1704436
UMLS CUI [5]
C0011854
UMLS CUI [6]
C0011860
UMLS CUI [7]
C0021641
UMLS CUI [8]
C1257987
subjects taking medications known to affect inflammation and blood lipids (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents, hormone replacement, binging alcohol)
Description

Pharmaceutical Preparations Affecting Inflammation | Pharmaceutical Preparations Affecting Blood lipids | Steroids | Adrenergic beta-1 Receptor Antagonists | Thiazide Diuretics | Hypolipidemic Agents | Hormone replacement therapy | Alcohol intake above recommended sensible limits

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0021368
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0392760
UMLS CUI [2,3]
C0596192
UMLS CUI [3]
C0038317
UMLS CUI [4]
C0304516
UMLS CUI [5]
C0012802
UMLS CUI [6]
C0086440
UMLS CUI [7]
C0282402
UMLS CUI [8]
C0560219
subjects taking lcn-3pufa supplements within 6 months of study onset.
Description

Long chain n-3 PUFA Supplements

Type de données

boolean

Alias
UMLS CUI [1,1]
C0522095
UMLS CUI [1,2]
C0015689
UMLS CUI [1,3]
C0242295
Retour au début de la page

Similar models

Eligibility Cardiovascular Disease, Inflammation NCT01810003

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Age | Metabolic Syndrome
Item
men and women aged between 18 and 70 years with metabolic syndrome as defined by the international diabetes federation (idf) criteria
boolean
C0001779 (UMLS CUI [1])
C0524620 (UMLS CUI [2])
Stable body weight
Item
stable body weight for at least 3 months prior to randomization.
boolean
C0517386 (UMLS CUI [1])
Premenopausal state | Menstrual cycles regular
Item
pre-menopausal women with regular menstrual cycle (25-35 days)
boolean
C0232969 (UMLS CUI [1])
C2229012 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Plasma C-reactive protein measurement
Item
plasma crp > 10 g/ml at screening
boolean
C0428493 (UMLS CUI [1])
Dyslipidemias Extreme | Hypercholesterolemia, Familial
Item
extreme dyslipidemias such as familial hypercholesterolemia
boolean
C0242339 (UMLS CUI [1,1])
C0205403 (UMLS CUI [1,2])
C0020445 (UMLS CUI [2])
Cardiovascular Disease | Coronary heart disease | Cerebrovascular Disorder | Peripheral Arterial Disease | Diabetes Mellitus, Insulin-Dependent | Diabetes Mellitus, Non-Insulin-Dependent | Insulin | Thiazolidinediones
Item
previous history of cardiovascular disease (coronary heart disease, cerebrovascular disease or peripheral arterial disease) and type 1 or 2 diabetes or patients having received or being treated with insulin or a thiazolidinedione within the past 6 months
boolean
C0007222 (UMLS CUI [1])
C0010068 (UMLS CUI [2])
C0007820 (UMLS CUI [3])
C1704436 (UMLS CUI [4])
C0011854 (UMLS CUI [5])
C0011860 (UMLS CUI [6])
C0021641 (UMLS CUI [7])
C1257987 (UMLS CUI [8])
Pharmaceutical Preparations Affecting Inflammation | Pharmaceutical Preparations Affecting Blood lipids | Steroids | Adrenergic beta-1 Receptor Antagonists | Thiazide Diuretics | Hypolipidemic Agents | Hormone replacement therapy | Alcohol intake above recommended sensible limits
Item
subjects taking medications known to affect inflammation and blood lipids (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents, hormone replacement, binging alcohol)
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0021368 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0596192 (UMLS CUI [2,3])
C0038317 (UMLS CUI [3])
C0304516 (UMLS CUI [4])
C0012802 (UMLS CUI [5])
C0086440 (UMLS CUI [6])
C0282402 (UMLS CUI [7])
C0560219 (UMLS CUI [8])
Long chain n-3 PUFA Supplements
Item
subjects taking lcn-3pufa supplements within 6 months of study onset.
boolean
C0522095 (UMLS CUI [1,1])
C0015689 (UMLS CUI [1,2])
C0242295 (UMLS CUI [1,3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial